What we're scoring next.
A live log of programs we're re-scoring, programs queued for first-time scoring, and methodology questions we're working through.
In progress
Re-scores landing in the next 1 to 2 weeks.
Active
Ivim Health
Confirming tirzepatide tier pricing after their June 2026 restructure. Confirming whether the 4-month-commitment $175/mo floor still holds and what month-to-month looks like.
Active
Henry Meds
Pricing watch. Closed 2026-09-09: henrymeds.com/legal/programs is public again and publishes one price at every dose, $297 a month for the compounded semaglutide injection, with no membership fee. The $197 tier is the 12-month plan paid up front, a note and never the headline.
Active
Strut Health
Confirming the $99 standard-dose oral lozenge price vs injectable pricing. Distinction matters for the compounded floor copy across multiple pages.
Queued for first-time scoring
Programs we plan to enter the chart. Scoring needs at least 6 weeks of price + policy observation.
Queued
June PDF edition build
June Price Index PDF edition. Building after all June 10 price corrections are confirmed. Target: June 14 publish.
Methodology under review
Open questions about the scoring rubric. Email hello@glpchart.com with your take if any of these affect how you read the chart.
- How we weight the lock-in dimension. Considering a sub-axis for cancellation fees specifically (separate from minimum-term length).
- Whether to publish a per-state availability score. Currently a binary ships-or-not flag.
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.